{"rows":[{"id":"07dcaca9-369e-4607-b48c-89fd853d74be","studyId":"669a1dad-f40b-4044-b837-88898bd04f9f","studyCode":"RARE-007","studySponsor":"Northwind Genetics","title":"Sample size insufficient at current event rate","owner":"Biostatistics Lead","severity":"critical","status":"open","mitigation":"Type B FDA meeting requested to discuss adaptive SSR; protocol amendment v4 drafted."},{"id":"b730bd93-aec5-4911-acea-b8968f0c216b","studyId":"669a1dad-f40b-4044-b837-88898bd04f9f","studyCode":"RARE-007","studySponsor":"Northwind Genetics","title":"EAC has breached contracted budget","owner":"Finance Lead","severity":"high","status":"open","mitigation":"Change order in negotiation; sponsor steering committee notified."},{"id":"4463c795-85ed-49d0-9e76-8d2efa31d098","studyId":"c51233dc-35e6-4fa3-9cd5-9739940d50de","studyCode":"ONC-002","studySponsor":"Acme Therapeutics","title":"EU site activation delayed by competent authority backlog","owner":"Regulatory Lead","severity":"high","status":"mitigating","mitigation":"Escalated; two replacement US sites in qualification (target activation +45d)."},{"id":"ccfe4a13-346f-4b9b-a819-5ca919e17f13","studyId":"669a1dad-f40b-4044-b837-88898bd04f9f","studyCode":"RARE-007","studySponsor":"Northwind Genetics","title":"Patient identification network exhausted at top 5 sites","owner":"Feasibility Lead","severity":"high","status":"mitigating","mitigation":"Expanding to APAC region (3 new countries); RWD partnership signed."},{"id":"8e9bc204-4cc6-44d1-914d-c10491419ea0","studyId":"4f88e897-9005-45a5-adfd-f87244041f81","studyCode":"VAX-014","studySponsor":"Stellis Vaccines","title":"Manufacturing lot deviation on adjuvant lot ADJ-2025-04","owner":"CMC Lead","severity":"high","status":"mitigating","mitigation":"Lot quarantined; re-qualified replacement lot deployed; CAPA in regulatory review."},{"id":"aec672ed-edc9-42db-a688-555e6d4de9b8","studyId":"c51233dc-35e6-4fa3-9cd5-9739940d50de","studyCode":"ONC-002","studySponsor":"Acme Therapeutics","title":"Higher than expected screen failure on creatinine clearance criterion","owner":"Medical Monitor","severity":"medium","status":"open","mitigation":"Protocol amendment v3 in draft to relax CrCl from 60 to 50 mL/min."},{"id":"08a0f8cf-a376-4a13-a021-fe35fa7511d8","studyId":"4f88e897-9005-45a5-adfd-f87244041f81","studyCode":"VAX-014","studySponsor":"Stellis Vaccines","title":"Central lab assay validation re-run required after method update","owner":"Lab Lead","severity":"medium","status":"open","mitigation":"Re-run scheduled; analytical bridge plan agreed."},{"id":"9caad0de-f2c6-4ac8-8ce0-c66fc165a4ac","studyId":"def65e64-3385-4b3a-898b-25d0d2d5f405","studyCode":"CV-118","studySponsor":"Helios Cardio","title":"CSR authoring vendor capacity over Q1 2027","owner":"Medical Writing Lead","severity":"medium","status":"mitigating","mitigation":"Backup author identified; CSR shell pre-built."},{"id":"25d8c0fc-e34e-42b0-bd43-880fbe774165","studyId":"40ce4729-34ce-41ce-b85c-4aae5203e5bc","studyCode":"DERM-003","studySponsor":"Lyra Skin Sciences","title":"Single-source device component supply","owner":"Supply Chain Lead","severity":"medium","status":"mitigating","mitigation":"Buffer stock at 3 months; second-source qualification in progress."},{"id":"f08a6505-f9ca-49ac-b1ea-2e18f697457e","studyId":"1d52549c-1630-4e9e-a055-af10ac1d33ba","studyCode":"OBS-PMR-001","studySponsor":"Veridian Pharma","title":"Vendor archive handoff for 6-year retention obligation","owner":"Records Lead","severity":"medium","status":"mitigating","mitigation":"Long-term archive contract executed; index re-verified."},{"id":"f65ada5f-e8c8-449e-924a-ab72f137ce87","studyId":"c51233dc-35e6-4fa3-9cd5-9739940d50de","studyCode":"ONC-002","studySponsor":"Acme Therapeutics","title":"CRO sub-contracting central lab going through M&A","owner":"CRA Manager","severity":"medium","status":"mitigating","mitigation":"Continuity letter on file; back-up lab identified."},{"id":"0631fcc6-272a-42c3-ace6-666332b79013","studyId":"669a1dad-f40b-4044-b837-88898bd04f9f","studyCode":"RARE-007","studySponsor":"Northwind Genetics","title":"Central reader inter-rater variability above threshold","owner":"Medical Monitor","severity":"medium","status":"mitigating","mitigation":"Retraining and re-adjudication of 12% of reads in progress."},{"id":"731e39a6-9757-4eee-8d33-444cb26b8cb0","studyId":"669a1dad-f40b-4044-b837-88898bd04f9f","studyCode":"RARE-007","studySponsor":"Northwind Genetics","title":"IRT vendor outage on 2026-04-12 caused 14 mis-randomisations","owner":"Data Management Lead","severity":"medium","status":"closed","mitigation":"Vendor RCA delivered; all subjects reconciled; CAPA closed."},{"id":"d8d12ac7-9598-470e-a11e-d12ab394c848","studyId":"4f88e897-9005-45a5-adfd-f87244041f81","studyCode":"VAX-014","studySponsor":"Stellis Vaccines","title":"Reactogenicity rate slightly above comparator","owner":"Medical Monitor","severity":"medium","status":"closed","mitigation":"Independent DSMB review at 50% enrolment: continue unchanged."},{"id":"19254e78-821e-436e-aaac-6168e3fa28db","studyId":"def65e64-3385-4b3a-898b-25d0d2d5f405","studyCode":"CV-118","studySponsor":"Helios Cardio","title":"Event rate slightly below DSMB-projected curve","owner":"Biostatistics Lead","severity":"low","status":"mitigating","mitigation":"On track per pre-specified contingency; LPLV trigger by event count, not date."},{"id":"3de7ddf6-c23d-450f-9bd9-f85a7c43cfc2","studyId":"def65e64-3385-4b3a-898b-25d0d2d5f405","studyCode":"CV-118","studySponsor":"Helios Cardio","title":"Long-tail subject retention in Eastern Europe","owner":"CRA Manager","severity":"low","status":"mitigating","mitigation":"Retention stipend uplift approved; LTFU still 3.1%, below 4% threshold."},{"id":"a12b43f4-f040-4a88-bfc9-36506ea570a5","studyId":"40ce4729-34ce-41ce-b85c-4aae5203e5bc","studyCode":"DERM-003","studySponsor":"Lyra Skin Sciences","title":"CE-mark renewal aligned with EU MDR transition","owner":"Regulatory Lead","severity":"low","status":"mitigating","mitigation":"Notified body engaged; renewal dossier on track for Q4 2026."},{"id":"9215042a-0405-4d7a-a65f-85b160e931ee","studyId":"1d52549c-1630-4e9e-a055-af10ac1d33ba","studyCode":"OBS-PMR-001","studySponsor":"Veridian Pharma","title":"Publication concurrency with sponsor PR cycle","owner":"Medical Writing Lead","severity":"low","status":"mitigating","mitigation":"Joint editorial calendar agreed."},{"id":"f766a4f6-5a19-4711-8350-46f7e2136498","studyId":"4f88e897-9005-45a5-adfd-f87244041f81","studyCode":"VAX-014","studySponsor":"Stellis Vaccines","title":"Seasonal enrolment dip projected through Q3","owner":"CRA Manager","severity":"low","status":"mitigating","mitigation":"Southern hemisphere sites in start-up to offset."},{"id":"74fba5d3-bf77-4300-8d34-2c9f8ba9573f","studyId":"40ce4729-34ce-41ce-b85c-4aae5203e5bc","studyCode":"DERM-003","studySponsor":"Lyra Skin Sciences","title":"Subjective endpoint reader drift","owner":"Medical Monitor","severity":"low","status":"closed","mitigation":"Calibration sessions every 90 days; QC audit at 50% enrolment passed."},{"id":"d36787c1-9b0f-4bb8-9282-2dcc24317d99","studyId":"1d52549c-1630-4e9e-a055-af10ac1d33ba","studyCode":"OBS-PMR-001","studySponsor":"Veridian Pharma","title":"Late-arriving AE narratives at DB lock","owner":"Pharmacovigilance Lead","severity":"low","status":"closed","mitigation":"All narratives QC-cleared; lock executed without amendment."},{"id":"79f1be64-dc3c-474e-9f4b-571b7241785d","studyId":"c51233dc-35e6-4fa3-9cd5-9739940d50de","studyCode":"ONC-002","studySponsor":"Acme Therapeutics","title":"Investigator turnover at top-3 enrolling site","owner":"CRA Manager","severity":"low","status":"closed","mitigation":"Sub-investigator certified and trained."}],"totals":{"all":22,"open":4,"mitigating":13,"closed":5,"criticals":1}}